High unbound flucloxacillin fraction in critically ill patients. (31st August 2021)

• Record Type: Journal Article
• Authors: Wallenburg, Eveline; ter Heine, Rob; de Lange, Dylan W; van Leeuwen, Henk; Schouten, Jeroen A; ten Oever, Jaap; Kolwijck, Eva; Burger, David M; Pickkers, Peter; Gieling, Emilie M; de Maat, Monique M; Frenzel, Tim; Brüggemann, Roger J
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 76:Number 12(2021)
• Page Start: 3220
• Page End: 3228
• Publication Date: 2021-08-31
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkab314
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Objectives: To describe the unbound and total flucloxacillin pharmacokinetics in critically ill patients and to define optimal dosing strategies. Patients and methods: Observational multicentre study including a total of 33 adult ICU patients receiving flucloxacillin, given as intermittent or continuous infusion. Pharmacokinetic sampling was performed on two occasions on two different days. Total and unbound flucloxacillin concentrations were measured and analysed using non-linear mixed-effects modelling. Serum albumin was added as covariate on the maximum binding capacity and endogenous creatinine clearance (CLCR ) as covariate for renal function. Monte Carlo simulations were performed to predict the unbound flucloxacillin concentrations for different dosing strategies and different categories of endogenous CLCR . Results: The measured unbound concentrations ranged from 0.2 to 110 mg/L and the observed unbound fraction varied between 7.0% and 71.7%. An integral two-compartmental linear pharmacokinetic model based on total and unbound concentrations was developed. A dose of 12 g/24 h was sufficient for 99.9% of the population to achieve a concentration of >2.5 mg/L (100% fT >5×MIC, MIC = 0.5 mg/L). Conclusions: Critically ill patients show higher unbound flucloxacillin fractions and concentrations than previously thought. Consequently, the risk of subtherapeutic exposure is low.